WomenHeart announces Science & Leadership Symposium graduates for 2013
WASHINGTON — Nearly two dozen women with heart disease will educate their communities about heart disease in women.
WomenHeart, a group focused on heart disease in women, said 23 women had graduated from the WomenHeart Science & Leadership Symposium at the Mayo Clinic in Rochester, Minn., to become WomenHeart Champions. The symposium is sponsored by the Medtronic Foundation, Boston Scientific, Edwards Lifesciences, Gilead, Astellas Pharma, AstraZeneca, Novartis, St. Jude Medical Foundation, Bristol-Myers Squibb and Genentech. The 2013 graduates join 628 graduates from previous years to become the "boots on the ground" to spread awareness about heart disease, the organization said; the symposium started in 2002.
"Heart disease can be a very emotionally and physically isolating condition for women," WomenHeart CEO Lisa Tate said. "WomenHeart Champions and the support networks that they build enable women to have the peer-to-peer support they need to make the lifestyle changes necessary to live a heart-healthy life."
Heart disease is the leading cause of death in women, and more women than men have died from heart disease every year since 1984, according to the group.
Reports: Oregon Board of Pharmacy head to step down
NEW YORK — The executive director of the Oregon Board of Pharmacy is leaving, according to published reports.
The Lund Report, an online publication that covers Oregon’s healthcare system, reported that Gary Schnabel was stepping down to pursue "other interests." Schnabel turned 65 years old this month and has lead the board for 19 years.
Highlights from Schnabel’s career include being invited by former Sen. Gordon Smith, R-Ore., in January 2005 to testify before Congress on the state’s experience with selling drugs online, just before the confirmation of then-Secretary of State Condoleezza Rice.
According to The Lund Report, Schnabel intends to work as a consultant, doing on-site inspections of compounding pharmacies for the National Association of Boards of Pharmacy and consulting with drug companies.
Mission Pharmacal successfully defends patent protecting prescription-only prenatal vitamin brands through 2020
SAN ANTONIO — Mission Pharmacal on Wednesday announced that a federal district court in Texas has upheld its patent that covers the company’s prescription-only prenatal vitamin brands. "Mission Pharmacal has successfully asserted the dual-iron (‘247) patent used in its popular CitraNatal family of prenatal vitamins, preserving Mission Pharmacal’s high quality formulation pregnant women have counted on for years," stated Mission Pharmacal general counsel Lee Cusenbary.
The U.S. District Court for the Western District of Texas has entered a consent judgment against PureTek Corporation that requires it to stop manufacturing its RE OB+DHA and PNV OB+DHA products that infringe Mission Pharmacal’s ‘247 patent. "The U.S. Patent and Trademark Office confirmed the validity of the ‘247 patent during a reexamination, and this ruling reconfirms that validity," Cusenbary said. The patent protects CitraNatal’s use of a specific combination of iron that combats iron deficiency anemia before, during and after pregnancy.
"The dual-iron formulation used in these supplements helps pregnant women get the iron they need, yet it is gentle on the gastrointestinal system," commented Nancy Price, CitraNatal senior product manager. "The CitraNatal family of prenatal supplements provides optimal nutrition, which is essential for the health of moms and babies. CitraNatal’s gentle-but-effective patented iron delivery system helps to keep moms more comfortable throughout pregnancy."
This is the second time Mission Pharmacal has successfully asserted this patent, Price noted. In 2010, another generic manufacturer agreed that it had violated the patent and took its product off the market.
This ruling preserves Mission Pharmacal’s exclusive use of the formulation featured in the CitraNatal and Ferralet 90 products until 2020.